Feed ICLR
IC

ICON ICLR · NASDAQ

$211.36 -1.91% (-$4.12)

Market cap
$16.6B
Enterprise value
$19.3B
P/E
37.1x
Forward P/E
19.9x
PEG
-
P/S
2.0x
P/FCF
13.0x
EV/EBITDA
14.1x
ROIC
4.8%
Gross margin
21.2%
Net margin
5.4%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
2.0x
Beta
1.24
Free float
99.0%

About the company

ICON Public Limited Company (ICLR) is a global company providing solutions in the field of drug research and development and biotechnology. The company offers comprehensive services including clinical research, consulting, and strategic planning for pharmaceutical, biotechnology, and medical companies. Their portfolio includes a wide range of services from study design to commercial drug development and support for post-market activities. ICON focuses on providing high quality and efficiency in all stages of drug development to help customers accelerate the drug development process and improve the success of their products. The company also actively invests in innovations and technological advancements to provide the latest and best solutions for its clients. ICON Public Limited Company (ICLR) shares may be attractive to investors seeking investments in companies operating in the field of drug research and development and biotechnology with a global reach and a strong background in research and innovation.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Barry Balfe

Employees

40,200

Headquarters

Dublin

Valuation

Is today's price reasonable?

  • What to watch: The share price is above the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What to watch: Earnings per share fell by 22% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 16 USD is left as free cash.
  • What to watch: It earns only 4.8 USD a year on every 100 USD of invested capital.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

  • What speaks for it: It bought back its own shares for $750.0M in the last fiscal year, 4.5% of its market value.

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy